- Reimbursed by 95% of managed care organizations1
- Greatest access to a preferred formulary position at managed care organizations among branded alpha-blockers†,1
 |
See data from clinical trials |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
† Comparison based on the branded alpha-blockers Cardura®, FLOMAX, Hytrin®, Minipress®, and Uroxatral®.
1. Verispan’s Managed Care Formulary Drug Audit, Spring 2007.
All registered trademarks are owned by their respective companies.
